| Record Information |
|---|
| Version | 2.0 |
|---|
| Created at | 2022-02-14 20:57:06 UTC |
|---|
| Updated at | 2022-03-10 22:21:21 UTC |
|---|
| NP-MRD ID | NP0044458 |
|---|
| Secondary Accession Numbers | None |
|---|
| Natural Product Identification |
|---|
| Common Name | Inositol 1,3,4,5-tetraphosphate |
|---|
| Description | Inositol 1,3,4,5-tetraphosphate, also known as ins-1,3,4,5-P4, belongs to the class of organic compounds known as inositol phosphates. Inositol phosphates are compounds containing a phosphate group attached to an inositol (or cyclohexanehexol) moiety. Inositol 1,3,4,5-tetraphosphate is an extremely strong acidic compound (based on its pKa). Within humans, inositol 1,3,4,5-tetraphosphate participates in a number of enzymatic reactions. In particular, inositol 1,3,4,5-tetraphosphate can be converted into inositol 1,3,4,5,6-pentakisphosphate through its interaction with the enzyme inositol polyphosphate multikinase. In addition, inositol 1,3,4,5-tetraphosphate can be biosynthesized from inositol 1,3,4-trisphosphate through its interaction with the enzyme inositol-tetrakisphosphate 1-kinase. Evidence shows that IP4 can activate a protein with ras- and rap-GAP activity and finally inactivate the G protein. Inositol 1,3,4,5-tetrakisphopsphate (IP4) is a second messenger responsible for mediating Ca2+ entry through plasma membrane and mobilize intracellular Ca2+ by acting synergistically with inositol 1,4,5-trisphosphate (IP3). Inositol 1,3,4,5-tetraphosphate is also a substrate for Type I inositol-1,4,5-trisphosphate 5-phosphatase, Phosphatidylinositol 4,5-bisphosphate 5-phosphatase A and Skeletal muscle and kidney enriched inositol phosphatase. IP4 can bind with high affinity to several intracellular proteins: Synaptotagmin (I and II), Gap1, Btk, and centaurin-alpha-and may interact with synaptotagmin to inhibit synaptic transmission. Inositol 1,4,5-trisphosphate 3-kinase (IP3K, EC2.7.1.127) Phosphorylates IP3 to IP4. In humans, inositol 1,3,4,5-tetraphosphate is involved in inositol phosphate metabolism. IP4 production is not always associated with modification in calcium concentration, and control of calcium mobilization is not the sole function proposed for IP4. IP4 define an essential signaling pathway for T cell precursor responsiveness and development. This indicates that IP4 regulates Ca2+ influx in a GTP-dependent way, which potentially links the IP3 signaling pathway to GTP-regulated signaling mechanisms. Inositol 1,3,4,5-tetraphosphate is expected to be in Cannabis as all living plants are known to produce and metabolize it. |
|---|
| Structure | [H][C@]1(O)C([H])(OP(O)(O)=O)[C@]([H])(O)[C@@]([H])(OP(O)(O)=O)C([H])(OP(O)(O)=O)[C@@]1([H])OP(O)(O)=O InChI=1S/C6H16O18P4/c7-1-3(21-25(9,10)11)2(8)5(23-27(15,16)17)6(24-28(18,19)20)4(1)22-26(12,13)14/h1-8H,(H2,9,10,11)(H2,12,13,14)(H2,15,16,17)(H2,18,19,20)/t1-,2-,3?,4-,5+,6?/m0/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| Inositol 1,3,4,5-tetraphosphoric acid | Generator | | 1,3,4,5-Tetrakis(dihydrogen phosphate) myo-inositol | HMDB | | 1D-Myo-inositol 1,3,4,5-tetrakis(dihydrogen phosphate) | HMDB | | 1D-Myo-inositol 1,3,4,5-tetrakisphosphate | HMDB | | D-Myo-inositol 1,3,4,5-tetrakisphosphate | HMDB | | Inositol 1,3,4,5-tetrakis(phosphate) | HMDB | | Inositol 1,3,4,5-tetrakisphosphate | HMDB | | Inositol-(1,3,4,5)-tetrakisphosphate | HMDB | | Inositol-1,3,4,5-tetrakisphosphate | HMDB | | Inositol-1,3,4,5-tetraphosphate | HMDB | | Ins-1,3,4,5-P4 | HMDB | | Myo-inositol 1,3,4,5-tetrakis(phosphate) | HMDB | | Myo-inositol 1,3,4,5-tetraphosphate | HMDB | | Myo-inositol, 1,3,4,5-tetrakis(dihydrogen phosphate) | HMDB | | Myo-inositol-1,3,4,5-tetrakisphosphate | HMDB | | [(2R,3S,5S,6S)-3,5-Dihydroxy-2,4,6-triphosphonooxycyclohexyl] dihydrogen phosphate | HMDB | | Inositol-1,3,4,5-tetrakisphosphate, DL-isomer | HMDB | | Ins(1,3,4,5)p(4) | HMDB | | Inositol-1,3,4,5-tetrakisphosphate, D-isomer | HMDB | | Ins(1,3,4,5)P4 | HMDB |
|
|---|
| Chemical Formula | C6H16O18P4 |
|---|
| Average Mass | 500.0755 Da |
|---|
| Monoisotopic Mass | 499.92871 Da |
|---|
| IUPAC Name | {[(1R,2S,4S,5S)-2,4-dihydroxy-3,5,6-tris(phosphonooxy)cyclohexyl]oxy}phosphonic acid |
|---|
| Traditional Name | [(1R,2S,4S,5S)-2,4-dihydroxy-3,5,6-tris(phosphonooxy)cyclohexyl]oxyphosphonic acid |
|---|
| CAS Registry Number | 102850-29-3 |
|---|
| SMILES | [H][C@]1(O)C([H])(OP(O)(O)=O)[C@]([H])(O)[C@@]([H])(OP(O)(O)=O)C([H])(OP(O)(O)=O)[C@@]1([H])OP(O)(O)=O |
|---|
| InChI Identifier | InChI=1S/C6H16O18P4/c7-1-3(21-25(9,10)11)2(8)5(23-27(15,16)17)6(24-28(18,19)20)4(1)22-26(12,13)14/h1-8H,(H2,9,10,11)(H2,12,13,14)(H2,15,16,17)(H2,18,19,20)/t1-,2-,3?,4-,5+,6?/m0/s1 |
|---|
| InChI Key | CIPFCGZLFXVXBG-FTSGZOCFSA-N |
|---|
| Experimental Spectra |
|---|
|
| Not Available | | Predicted Spectra |
|---|
|
| | Spectrum Type | Description | Depositor ID | Depositor Organization | Depositor | Deposition Date | View |
|---|
| 1D NMR | 13C NMR Spectrum (1D, 25 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 100 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 252 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 1000 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 50 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 200 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 75 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 300 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 101 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 400 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 126 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 500 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 151 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 600 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 176 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 700 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 201 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 800 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 226 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 900 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum |
| | Chemical Shift Submissions |
|---|
|
| Not Available | | Species |
|---|
| Species of Origin | |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as inositol phosphates. Inositol phosphates are compounds containing a phosphate group attached to an inositol (or cyclohexanehexol) moiety. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organic oxygen compounds |
|---|
| Class | Organooxygen compounds |
|---|
| Sub Class | Alcohols and polyols |
|---|
| Direct Parent | Inositol phosphates |
|---|
| Alternative Parents | |
|---|
| Substituents | - Inositol phosphate
- Monoalkyl phosphate
- Cyclohexanol
- Alkyl phosphate
- Phosphoric acid ester
- Organic phosphoric acid derivative
- Secondary alcohol
- Organic oxide
- Hydrocarbon derivative
- Aliphatic homomonocyclic compound
|
|---|
| Molecular Framework | Aliphatic homomonocyclic compounds |
|---|
| External Descriptors | Not Available |
|---|
| Physical Properties |
|---|
| State | Not Available |
|---|
| Experimental Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Predicted Properties | |
|---|
| General References | - Cozier GE, Lockyer PJ, Reynolds JS, Kupzig S, Bottomley JR, Millard TH, Banting G, Cullen PJ: GAP1IP4BP contains a novel group I pleckstrin homology domain that directs constitutive plasma membrane association. J Biol Chem. 2000 Sep 8;275(36):28261-8. doi: 10.1074/jbc.M000469200. [PubMed:10869341 ]
- Horne G, Potter BV: Synthesis of the enantiomers of 6-deoxy-myo-inositol 1,3,4,5-tetrakisphosphate, structural analogues of myo-inositol 1,3,4,5-tetrakisphosphate. Chemistry. 2001 Jan 5;7(1):80-7. doi: 10.1002/1521-3765(20010105)7:1<80::aid-chem80>3.0.co;2-b. [PubMed:11205029 ]
- Han SY, Kato H, Kato S, Suzuki T, Shibata H, Ishii S, Shiiba K, Matsuno S, Kanamaru R, Ishioka C: Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay. Cancer Res. 2000 Jun 15;60(12):3147-51. [PubMed:10866302 ]
- Xia HJ, Yang G: Inositol 1,4,5-trisphosphate 3-kinases: functions and regulations. Cell Res. 2005 Feb;15(2):83-91. doi: 10.1038/sj.cr.7290270. [PubMed:15740635 ]
- Pouillon V, Hascakova-Bartova R, Pajak B, Adam E, Bex F, Dewaste V, Van Lint C, Leo O, Erneux C, Schurmans S: Inositol 1,3,4,5-tetrakisphosphate is essential for T lymphocyte development. Nat Immunol. 2003 Nov;4(11):1136-43. doi: 10.1038/ni980. Epub 2003 Sep 28. [PubMed:14517551 ]
|
|---|